Radiation plus immunotherapy shows promise for men with limited prostate cancer spread
NCT ID NCT03795207
First seen Apr 07, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study is for men whose prostate cancer has returned and spread to a few spots (up to 5) in the bones or lymph nodes. It compares standard radiation therapy alone versus radiation plus an immunotherapy drug called durvalumab. The goal is to see if adding the drug helps keep the cancer from growing longer. About 96 men will take part, and the treatment lasts up to 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Brest
Brest, 29200, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Chbs Lorient
Lorient, 56100, France
-
Hospices Civils de Lyon
Pierre-Bénite, 69310, France
-
ICO
Saint-Herblain, 44805, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut de Cancérologie de Montpellier
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.